What question did this study set out to answer?

The study aims to explore the role of the lncRNA SEAL1 in regulating myCAF cell state and its implications for therapy in solid cancers.

April 5, 2026

Abstract 3513: The novel lncRNA SEAL1 - key regulator of the pan-cancer myCAF cell state dictating prognosis ans immunotherapy response - is a promising new therapeutic target for solid cancers

Key Points

The study aims to explore the role of the lncRNA SEAL1 in regulating myCAF cell state and its implications for therapy in solid cancers.
Identified SEAL1 expression in myCAFs across various solid cancers.
Utilized antisense oligonucleotide (ASO) to target SEAL1 in vitro and in vivo.
Examined the impact of SEAL1 and LRRC15 targeting on myCAF identity and tumor volume.
SEAL1 is restrictively expressed in myCAFs associated with poor prognosis.
Targeting SEAL1 significantly reduced myCAF identity in cellular models.
Targeting SEAL1 in xenograft models led to reduced tumor volumes, highlighting its therapeutic potential.

Abstract

Abstract A desmoplastic reaction in the solid tumor microenvironment (TME), typically characterized by extracellular matrix (ECM) dysregulation and an immune suppressive milieu, is a key factor contributing to tumor aggression, therapeutic resistance, metastasis and inevitably poor patient prognosis. Cancer-associated fibroblasts (CAFs), in particular myofibroblast-like CAFs (myCAFs), are central players in the development of TME desmoplasia in the most common and aggressive solid cancers such as breast, lung, head Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3513.

Ask AI

Helpful

Bookmark